Profile data is unavailable for this security.
About the company
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
- Revenue in USD (TTM)0.00
- Net income in USD-17.19m
- Incorporated2006
- Employees29.00
- LocationBrainstorm Cell Therapeutics Inc1325 Avenue Of Americas, 28Th FloorNEW YORK 10019United StatesUSA
- Phone+1 (201) 488-0460
- Fax+1 (302) 655-5049
- Websitehttps://brainstorm-cell.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incannex Healthcare Inc | 163.39k | -13.70m | 35.24m | -- | -- | 1.87 | -- | 215.67 | -0.3806 | -0.3806 | 0.0003 | 1.19 | 0.0038 | -- | 0.0554 | -- | -31.42 | -54.94 | -32.90 | -59.47 | -- | -- | -8,386.19 | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| Vyne Therapeutics Inc | 424.00k | -27.87m | 35.25m | 10.00 | -- | 0.3972 | -- | 83.13 | -6.84 | -7.00 | 0.0413 | 6.29 | 0.0061 | -- | 0.1639 | 42,400.00 | -40.27 | -108.41 | -45.86 | -138.57 | -- | -- | -6,573.82 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Nuo Therapeutics Inc | 608.53k | -3.17m | 35.39m | -- | -- | 34.06 | -- | 58.16 | -0.0754 | -0.0754 | 0.0145 | 0.0235 | 0.2471 | 0.5609 | 3.55 | -- | -128.78 | -116.16 | -173.76 | -354.84 | 79.28 | 70.02 | -521.17 | -854.53 | 2.01 | -1,002.61 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
| Rapid Micro Biosystems Inc | 22.52m | -52.47m | 35.44m | 193.00 | -- | 0.3399 | -- | 1.57 | -1.22 | -1.22 | 0.5234 | 2.78 | 0.1348 | 1.36 | 4.07 | 116,678.80 | -31.41 | -- | -35.44 | -- | -24.36 | -- | -232.99 | -- | 5.29 | -- | 0.0026 | -- | 31.44 | -- | 13.71 | -- | -- | -- |
| Qsam Biosciences Inc | 0.00 | -5.16m | 35.56m | 4.00 | -- | 176.98 | -- | -- | -1.58 | -1.58 | 0.00 | 0.1863 | 0.00 | -- | -- | 0.00 | -424.48 | -944.58 | -- | -- | -- | -- | -- | -- | -- | -74.82 | 0.011 | -- | -- | -- | 15.04 | -- | -- | -- |
| Unicycive Therapeutics Inc | 675.00k | -31.41m | 35.80m | 14.00 | -- | -- | -- | 53.04 | -1.62 | -1.62 | 0.0276 | -0.1096 | 0.0794 | -- | -- | 48,214.29 | -359.15 | -218.20 | -- | -609.54 | -- | -- | -4,525.04 | -3,877.49 | -- | -- | -- | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Cyclo Therapeutics Inc | 1.08m | -20.06m | 36.18m | 8.00 | -- | 7.56 | -- | 33.61 | -1.33 | -1.33 | 0.0679 | 0.1666 | 0.1233 | 0.387 | 12.14 | 134,551.30 | -229.72 | -132.22 | -727.50 | -215.17 | 90.85 | 90.37 | -1,863.35 | -1,114.04 | 1.42 | -2,769.34 | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -17.19m | 36.53m | 29.00 | -- | -- | -- | -- | -0.4079 | -0.4079 | 0.00 | -0.0803 | 0.00 | -- | -- | 0.00 | -271.62 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| NKGen Biotech Inc | 0.00 | -82.95m | 36.72m | 63.00 | -- | -- | -- | -- | -5.24 | -5.24 | 0.00 | -2.68 | 0.00 | -- | -- | 0.00 | -86.93 | -- | -111.69 | -- | -- | -- | -- | -- | -- | -0.6077 | -- | -- | -- | -- | -1,923.83 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 0.00 | -30.16m | 37.13m | 2.00 | -- | -- | -- | -- | -2.95 | -2.95 | 0.00 | -0.1398 | 0.00 | -- | -- | -- | -182.00 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -2.16m | 37.34m | -- | -- | 3.57 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
| Cara Therapeutics Inc | 20.97m | -118.51m | 37.40m | 55.00 | -- | 0.6531 | -- | 1.78 | -2.19 | -2.19 | 0.3872 | 1.05 | 0.1361 | 2.37 | 6.96 | 381,236.40 | -76.94 | -35.76 | -91.50 | -40.82 | 70.56 | -- | -565.21 | -162.10 | 4.43 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Promis Neurosciences Inc | 0.00 | -13.21m | 37.54m | 6.00 | -- | 9.96 | -- | -- | -1.22 | -1.22 | 0.00 | 0.1987 | 0.00 | -- | -- | 0.00 | -128.63 | -144.28 | -552.70 | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| Xilio Therapeutics Inc | 0.00 | -76.40m | 37.58m | 73.00 | -- | 0.8171 | -- | -- | -2.78 | -2.78 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -76.37 | -- | -93.74 | -- | -- | -- | -- | -- | -- | -131.89 | 0.0826 | -- | -- | -- | 13.40 | -- | -- | -- |
| NextCure Inc | 0.00 | -62.72m | 37.67m | 82.00 | -- | 0.3292 | -- | -- | -2.25 | -2.25 | 0.00 | 4.10 | 0.00 | -- | -- | 0.00 | -40.18 | -22.59 | -42.35 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Zyversa Therapeutics Inc | 0.00 | -106.25m | 37.90m | 7.00 | -- | 0.1826 | -- | -- | -1,922.89 | -1,922.89 | 0.00 | 27.33 | 0.00 | -- | -- | 0.00 | -139.81 | -- | -160.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Brainstorm Cell Therapeutics Inc's reporting currency: US Dollar USD
6.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.41m | 2.88% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 460.03k | 0.94% |
| Geode Capital Management LLCas of 31 Dec 2023 | 357.04k | 0.73% |
| Liberty Wealth Management LLCas of 31 Dec 2023 | 340.15k | 0.69% |
| Weaver Consulting Group LLCas of 31 Mar 2024 | 199.36k | 0.41% |
| Caldwell Sutter Capital, Inc. (Investment Management)as of 31 Mar 2024 | 157.01k | 0.32% |
| Abner, Herrman & Brock LLCas of 31 Mar 2024 | 145.50k | 0.30% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Dec 2023 | 115.79k | 0.24% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 96.06k | 0.20% |
| Ikarian Capital LLCas of 31 Dec 2023 | 90.24k | 0.18% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
